DaVita Stock Declines After Outlook Miss, Berkshire Hathaway Sales

Dow Jones

Feb 15, 2025

By Katherine Hamilton

DaVita shares fell after the company's 2025 earnings missed expectations and Berkshire Hathaway sold shares in the company.

The stock declined 10% to $158.96 on Friday, though it is up about 30% over the past year.

Berkshire's sale of the shares has been in the works for months, but came on the heels of DaVita's fourth-quarter earnings. They showed the company is less optimistic about 2025 earnings than Wall Street has been.

Berkshire Chairman Warren Buffett sold 203,091 shares at $156.01 a share, offloading a total of $31.7 million, according to a Thursday filing with the Securities and Exchange Commission. Berkshire still has 35.9 million shares, making it the kidney dialysis company's largest stakeholder.

DaVita said in May it would buy back stock from Berkshire when its ownership surpassed 45%. Berkshire's sale this week brings its stake back down to that level.

Shares of DaVita began falling Thursday night before Berkshire's sale became public. After the bell, the healthcare company guided for adjusted earnings of $10.20 to $11.30 in 2025, below analysts' expectations of $11.38.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

February 14, 2025 14:35 ET (19:35 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2511611920"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2511611920\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2511611920?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-15 03:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2511611920","market":"hk","top_or_hot":-1,"title":"DaVita Stock Declines After Outlook Miss, Berkshire Hathaway Sales","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre>\n \n</pre>\n<p>\n  DaVita shares fell after the company's 2025 earnings missed expectations and Berkshire Hathaway sold shares in the company. \n</p>\n<p>\n  The stock declined 10% to $158.96 on Friday, though it is up about 30% over the past year. \n</p>\n<p>\n  Berkshire's sale of the shares has been in the works for months, but came on the heels of DaVita's fourth-quarter earnings. They showed the company is less optimistic about 2025 earnings than Wall Street has been. \n</p>\n<p>\n  Berkshire Chairman Warren Buffett sold 203,091 shares at $156.01 a share, offloading a total of $31.7 million, according to a Thursday filing with the Securities and Exchange Commission. Berkshire still has 35.9 million shares, making it the kidney dialysis company's largest stakeholder. \n</p>\n<p>\n  DaVita said in May it would buy back stock from Berkshire when its ownership surpassed 45%. Berkshire's sale this week brings its stake back down to that level. \n</p>\n<p>\n  Shares of DaVita began falling Thursday night before Berkshire's sale became public. After the bell, the healthcare company guided for adjusted earnings of $10.20 to $11.30 in 2025, below analysts' expectations of $11.38. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 14, 2025 14:35 ET (19:35 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DaVita Stock Declines After Outlook Miss, Berkshire Hathaway Sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDaVita Stock Declines After Outlook Miss, Berkshire Hathaway Sales\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-02-15 03:35</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre>\n \n</pre>\n<p>\n  DaVita shares fell after the company's 2025 earnings missed expectations and Berkshire Hathaway sold shares in the company. \n</p>\n<p>\n  The stock declined 10% to $158.96 on Friday, though it is up about 30% over the past year. \n</p>\n<p>\n  Berkshire's sale of the shares has been in the works for months, but came on the heels of DaVita's fourth-quarter earnings. They showed the company is less optimistic about 2025 earnings than Wall Street has been. \n</p>\n<p>\n  Berkshire Chairman Warren Buffett sold 203,091 shares at $156.01 a share, offloading a total of $31.7 million, according to a Thursday filing with the Securities and Exchange Commission. Berkshire still has 35.9 million shares, making it the kidney dialysis company's largest stakeholder. \n</p>\n<p>\n  DaVita said in May it would buy back stock from Berkshire when its ownership surpassed 45%. Berkshire's sale this week brings its stake back down to that level. \n</p>\n<p>\n  Shares of DaVita began falling Thursday night before Berkshire's sale became public. After the bell, the healthcare company guided for adjusted earnings of $10.20 to $11.30 in 2025, below analysts' expectations of $11.38. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 14, 2025 14:35 ET (19:35 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BRK.A","symbol_name":"伯克希尔","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2511611920","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2511611920","pubTimestamp":1739561700,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"DaVita shares fell after the company's 2025 earnings missed expectations and Berkshire Hathaway sold shares in the company.The stock declined 10% to $158.96 on Friday, though it is up about 30% over the past year.Berkshire's sale of the shares has been in the works for months, but came on the heels of DaVita's fourth-quarter earnings. They showed the company is less optimistic about 2025 earnings than Wall Street has been.Berkshire Chairman Warren Buffett sold 203,091 shares at $156.01 a share, offloading a total of $31.7 million, according to a Thursday filing with the Securities and Exchange Commission. Berkshire still has 35.9 million shares, making it the kidney dialysis company's largest stakeholder.DaVita said in May it would buy back stock from Berkshire when its ownership surpassed 45%. Berkshire's sale this week brings its stake back down to that level.Shares of DaVita began falling Thursday night before Berkshire's sale became public. After the bell, the healthcare company gu","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BRK.A":"伯克希尔","BRK.B":"伯克希尔B","DVA":"达维塔保健"},"translate_title":"伯克希尔哈撒韦公司出售前景未达预期后，DaVita股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DVA":0.9,"BRK.A":1,"BRK.B":1},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  DaVita shares fell after the company's 2025 earnings missed expectations and Berkshire Hathaway sold shares in the company. \n\n\n  The stock declined 10% to $158.96 on Friday, though it is up about 30% over the past year. \n\n\n  Berkshire's sale of the shares has been in the works for months, but came on the heels of DaVita's fourth-quarter earnings. They showed the company is less optimistic about 2025 earnings than Wall Street has been. \n\n\n  Berkshire Chairman Warren Buffett sold 203,091 shares at $156.01 a share, offloading a total of $31.7 million, according to a Thursday filing with the Securities and Exchange Commission. Berkshire still has 35.9 million shares, making it the kidney dialysis company's largest stakeholder. \n\n\n  DaVita said in May it would buy back stock from Berkshire when its ownership surpassed 45%. Berkshire's sale this week brings its stake back down to that level. \n\n\n  Shares of DaVita began falling Thursday night before Berkshire's sale became public. After the bell, the healthcare company guided for adjusted earnings of $10.20 to $11.30 in 2025, below analysts' expectations of $11.38. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 14, 2025 14:35 ET (19:35 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}